There have been 50 recent insider transactions recorded for Enliven Therapeutics, Inc. (ELVN), including 14 buys and 34 sells. Total insider buying was valued at $19.84M and total insider selling at $9.04M.
Notable insiders with recent activity include Collins Helen Louise, Hohl Benjamin, Heyman Richard A.. Insider transactions can provide insights into how company leadership views the stock's valuation and future prospects.
Insider Transactions — ELVN
| Date |
Name |
Role |
Transaction |
Shares |
Avg. Price |
Value |
Shares Owned |
| 2026-03-25 |
Collins Helen Louise |
Chief Medical Officer |
Informative Sell |
40,000 |
$35.10 |
$1.4M |
25,000 |
| 2026-03-17 |
Collins Helen Louise |
Chief Medical Officer |
Informative Sell |
5,000 |
$27.76 |
$138.8K |
25,000 |
| 2026-03-10 |
Collins Helen Louise |
Chief Medical Officer |
Informative Sell |
10,129 |
$30.19 |
$305.83K |
25,000 |
| 2026-03-09 |
Collins Helen Louise |
Chief Medical Officer |
Informative Sell |
29,871 |
$30.02 |
$896.81K |
25,000 |
| 2026-03-06 |
Hohl Benjamin |
Chief Financial Officer |
Informative Sell |
10,000 |
$29.58 |
$295.84K |
51,000 |
| 2026-02-17 |
Heyman Richard A. |
Director |
Informative Sell |
1,230 |
$26.18 |
$32.2K |
22,647 |
| 2026-02-17 |
Collins Helen Louise |
Chief Medical Officer |
Informative Sell |
45,000 |
$26.17 |
$1.18M |
25,000 |
| 2026-02-12 |
Garland J. Scott |
Director |
RSU Award |
1,427 |
$27.16 |
$38.76K |
1,427 |
| 2026-02-12 |
Kunkel Lori Anne |
Director |
RSU Award |
17,126 |
$27.16 |
$465.14K |
17,126 |
| 2026-02-12 |
Gupta Rishi |
Director |
RSU Award |
1,580 |
$27.16 |
$42.91K |
1,580 |
| 2026-02-12 |
Heyman Richard A. |
Director |
RSU Award |
19,234 |
$27.16 |
$522.4K |
19,234 |
| 2026-02-12 |
Bauer Jake |
Director |
RSU Award |
17,126 |
$27.16 |
$465.14K |
17,126 |
| 2026-02-12 |
Collins Helen Louise |
Chief Medical Officer |
RSU Award |
25,000 |
- |
- |
25,000 |
| 2026-02-12 |
Ballal Rahul D. |
Director |
RSU Award |
17,126 |
$27.16 |
$465.14K |
17,126 |
| 2026-02-12 |
Derynck Mika K |
Director |
RSU Award |
17,126 |
$27.16 |
$465.14K |
17,126 |
| 2026-02-12 |
Hohl Benjamin |
Chief Financial Officer |
RSU Award |
25,000 |
- |
- |
61,000 |
| 2026-02-12 |
Lyssikatos Joseph P |
Chief Scientific Officer |
RSU Award |
18,750 |
- |
- |
18,750 |
| 2026-02-12 |
Patel Anish |
Chief Operating Officer |
RSU Award |
20,000 |
- |
- |
20,000 |
| 2026-02-06 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
5,000 |
$29.04 |
$145.22K |
740,188 |
| 2026-01-20 |
Heyman Richard A. |
Director |
Informative Sell |
718 |
$26.96 |
$19.35K |
23,877 |
| 2026-01-20 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
14,509 |
$26.90 |
$390.28K |
745,188 |
| 2026-01-09 |
Heyman Richard A. |
Director |
Informative Sell |
4,285 |
$25.00 |
$107.13K |
25,107 |
| 2026-01-09 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
50,000 |
$29.13 |
$1.46M |
765,188 |
| 2026-01-09 |
Patel Anish |
Chief Operating Officer |
Informative Sell |
243 |
$28.50 |
$6.93K |
215,011 |
| 2026-01-08 |
Heyman Richard A. |
Director |
Informative Sell |
1,620 |
$25.00 |
$40.5K |
25,545 |
| 2026-01-08 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
33,802 |
$24.92 |
$842.47K |
856,386 |
| 2026-01-07 |
Garland J. Scott |
Director |
Unknown |
13,508 |
$22.47 |
$303.52K |
- |
| 2026-01-07 |
Garland J. Scott |
Director |
RSU Award |
59,372 |
$15.47 |
$918.48K |
59,372 |
| 2025-12-22 |
Hohl Benjamin |
Chief Financial Officer |
Option Exercise |
13,000 |
$2.48 |
$32.24K |
36,000 |
| 2025-12-19 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
5,000 |
$16.84 |
$84.21K |
897,688 |
| 2025-12-17 |
Kunkel Lori Anne |
Director |
Option Exercise (Sell) |
15,958 |
$1.12 |
$17.87K |
3,741 |
| 2025-12-11 |
Fair Richard A. |
Officer |
Unknown |
- |
- |
- |
- |
| 2025-12-11 |
Fair Richard A. |
President and CEO |
RSU Award |
875,000 |
$18.77 |
$16.42M |
875,000 |
| 2025-12-08 |
Patel Anish |
Chief Operating Officer |
Informative Sell |
1,705 |
$21.78 |
$37.13K |
263,311 |
| 2025-11-19 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
492 |
$23.09 |
$11.36K |
902,688 |
| 2025-11-17 |
Kintz Samuel |
President and CEO |
Informative Sell |
12,500 |
$21.82 |
$272.74K |
890,392 |
| 2025-11-07 |
Patel Anish |
Chief Operating Officer |
Informative Sell |
613 |
$17.94 |
$11K |
269,974 |
| 2025-10-20 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
12,500 |
$22.08 |
$276.03K |
915,188 |
| 2025-10-17 |
Kintz Samuel |
President and CEO |
Informative Sell |
12,500 |
$21.33 |
$266.65K |
902,892 |
| 2025-10-07 |
Patel Anish |
Chief Operating Officer |
Informative Sell |
6,667 |
$20.10 |
$133.99K |
276,641 |
| 2025-09-29 |
Hohl Benjamin |
Chief Financial Officer |
Informative Sell |
3,250 |
$20.40 |
$66.29K |
23,000 |
| 2025-09-26 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
4,000 |
$20.25 |
$81.01K |
927,688 |
| 2025-09-26 |
Kintz Samuel |
President and CEO |
Informative Sell |
3,700 |
$20.06 |
$74.23K |
915,392 |
| 2025-09-23 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
1,500 |
$20.03 |
$30.05K |
931,688 |
| 2025-09-23 |
Kintz Samuel |
President and CEO |
Informative Sell |
2,800 |
$20.03 |
$56.08K |
919,092 |
| 2025-09-19 |
Kintz Samuel |
President and CEO |
Informative Sell |
1,000 |
$20.25 |
$20.25K |
921,892 |
| 2025-09-19 |
Lyssikatos Joseph P |
Chief Scientific Officer |
Informative Sell |
2,130 |
$20.02 |
$42.63K |
933,188 |
| 2025-09-17 |
Kintz Samuel |
President and CEO |
Informative Sell |
5,000 |
$19.09 |
$95.47K |
922,892 |
| 2025-09-08 |
Patel Anish |
Chief Operating Officer |
Informative Sell |
6,667 |
$20.24 |
$134.96K |
283,308 |
| 2025-08-27 |
Hohl Benjamin |
Chief Financial Officer |
Informative Sell |
3,250 |
$20.63 |
$67.04K |
23,000 |
■ Informative Buy/Sell — open market transaction (most significant)
■ Uninformative Buy — award, option exercise, conversion
■ Uninformative Sell — tax withholding, award vest sale
■ Neutral — gift, trust, expiry
